Baillie Gifford & Co
RVMD icon

Baillie Gifford & Co’s Revolution Medicines RVMD Stock Holding History

Baillie Gifford & Co’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.3M Buy
263,466
+76,394
+41% +$11.2M 0.04% 158
2026
Q1 		$18.2M Sell
187,072
-7,887
-4% -$796K 0.02% 186
2025
Q4 		$15.5M Buy
+194,959
New +$12.8M 0.01% 197

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Baillie Gifford & Co's RVMD Position: Q2 2026 in Review

Baillie Gifford & Co increased its Revolution Medicines (RVMD) stake by 41% in Q2 2026, buying an estimated $11.2M and bringing the position to 263,466 shares worth $49.3M. The position accounts for 0.04% of the portfolio, ranked #158.

Baillie Gifford & Co first reported a position in RVMD in Q4 2025 and has held it in 3 quarters since. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Baillie Gifford & Co held 263,466 shares of Revolution Medicines worth $49.3M as of Q2 2026.
  • Baillie Gifford & Co bought 76,394 Revolution Medicines shares in Q2 2026, an estimated $11.2M.
  • Revolution Medicines made up 0.04% of Baillie Gifford & Co's portfolio in Q2 2026, its #158 holding.
  • Baillie Gifford & Co first reported a position in Revolution Medicines in Q4 2025 and has held it in 3 quarters since.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Baillie Gifford & Co's 13F filing for Q2 2026, filed 6 Aug 2026.